Qupet 1% w/w10 gm

Qupet 1% w/w 10 gm is indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety profile of Qupet 1% w/w 10 gm was assessed in two clinical trials (Trial 1 and Trial 2) in 362 adult and pediatric patients two months of age and older with impetigo. The patients used at least one dose from a 5-day, twice a day regimen of Qupet 1% w/w 10 gm. Control groups included 361 patients who used placebo and 152 patients who used retapamulin ointment. The median age of the patients enrolled in the clinical trials was 10 years; 3 % of patients were 2 months to less than 2 years of age, 55 % of patients were 2 to less than 12 years of age, 11 % of patients were 12 to less than 18 years of age, and 31 % of patients were 18 years of age or older. Adverse reactions (rosacea and seborrheic dermatitis) were reported in 1 adult patient treated with Qupet 1% w/w 10 gm.

Potential for Microbial Overgrowth: The prolonged use of Qupet 1% w/w 10 gm may result in overgrowth of nonsusceptible bacteria and fungi. If such infections occur during therapy, discontinue use and institute appropriate supportive measures.

Any sign or symptom of overdose, either topically or by accidental ingestion, should be treated symptomatically. No specific antidote is known.

Store at 20ºC - 25ºC; excursions permitted to 15ºC to 30ºC. Keep away from light & moisture. Keep out of the reach of children.

Topical Antibiotic preparations

Pregnancy: There are no available data on the use of Qupet 1% w/w 10 gm in pregnant women to inform a drug associated risk. Systemic absorption of Qupet 1% w/w 10 gm in humans is negligible following topical administration of Qupet 1% w/w 10 gm (up to twice the concentration of the marketed formulation). Due to the negligible systemic exposure, it is not expected that maternal use of Qupet 1% w/w 10 gm will result in fetal exposure to the drug. Animal reproduction studies were not conducted with Qupet 1% w/w 10 gm. However, toxicity studies conducted in pregnant rats and rabbits administered the oral form of Qupet 1% w/w 10 gm showed no significant adverse developmental effects (at >10,000 times the maximum human plasma concentration seen with dermal application of Qupet 1% w/w 10 gm). The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.Lactation: No data are available regarding the presence of Qupet 1% w/w 10 gm in human milk, and the effects of Qupet 1% w/w 10 gm on the breastfed infant or on milk production. However, breastfeeding is not expected to result in exposure of the child to Qupet 1% w/w 10 gm due to the negligible systemic absorption of Qupet 1% w/w 10 gm in humans following topical administration of Qupet 1% w/w 10 gm. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Qupet 1% w/w 10 gm and any potential adverse effects on the breast-fed child from Qupet 1% w/w 10 gm or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of Qupet 1% w/w 10 gm in the treatment of impetigo have been established in pediatric patients 2 months to 17 years of age. Use of Qupet 1% w/w 10 gm in pediatric patients (2 months to 17 years of age) is supported by evidence from adequate and well-controlled studies of Qupet 1% w/w 10 gm in which 251 pediatric patients received at least one dose of Qupet 1% w/w 10 gm. The median age of the patients enrolled in the clinical trials was 10 years; 3% of patients were 2 months to less than 2 years of age, 55 % of patients were 2 to less than 12 years of age, 11% of patients were 12 to less than 18 years of age, and 31 % of patients were 18 years of age or older. In these studies, the maximum dose applied was approximately 0.5 g of Qupet 1% w/w 10 gm applied twice daily for up to 5 days (i.e., up to 10 applications total). The safety profile of Qupet 1% w/w 10 gm in pediatric patients 2 months and older was similar to that of adults. The safety and effectiveness of Qupet 1% w/w 10 gm in pediatric patients younger than 2 months of age have not been established.Geriatric Use: Clinical studies of Qupet 1% w/w 10 gm did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.